Imidazole, Triazole and tetrazole derivatives
    1.
    发明授权
    Imidazole, Triazole and tetrazole derivatives 失效
    咪唑,三唑和四唑衍生物

    公开(公告)号:US5567726A

    公开(公告)日:1996-10-22

    申请号:US374582

    申请日:1995-01-24

    摘要: Imidazole, triazole and tetrazole derivatives of formula (I) are selective agonists of 5-HT.sub.1 -like receptors and are therefore useful in the treatment of clinical conditions, in particular migraine and associated disorders, for which a selective agonist of these receptors is indicated, wherein the broken circle represents two non-adjacent double bonds in any position in the five-membered ring; two, three or four of V, W, X, Y and Z represent nitrogen and the remainder represent carbon provided that, when two of V, W, X, Y and Z represent nitrogen and the remainder represent carbon, then the said nitrogen atoms are in non-adjacent positions within the five-membered ring; E represents a bond or a straight or branched alkylene chain containing from 1 to 4 carbon atoms; F represents a group of formula (a); U represents nitrogen or C--R.sup.2 ; B represents oxygen, sulphur or N--R.sup.3 ; R.sup.1 represents a group of formula (i), (ii) or (iii).

    摘要翻译: PCT No.PCT / GB93 / 01495 Sec。 371日期1995年1月24日 102(e)1995年1月24日PCT PCT 1993年7月15日PCT公布。 第WO94 / 02477号公报 (i)式(I)的咪唑,三唑和四唑衍生物是选择性激动剂(I) 的5-HT1样受体,因此可用于治疗临床状况,特别是指示这些受体的选择性激动剂的偏头痛和相关病症,其中所述断圆代表任何位置的两个不相邻的双键 在五元环中; V,W,X,Y和Z中的两个,三个或四个表示氮,余数表示碳,条件是当V,W,X,Y和Z中的两个表示氮并且其余表示碳时,则所述氮原子 在五元环内的非相邻位置; E表示含有1至4个碳原子的键或直链或支链亚烷基链; F表示式(a)的基团。 U表示氮或C-R2; B代表氧,硫或N-R3; R1表示式(i),(ii)或(iii)的基团。

    Imidazole, triazole and tetrazole derivatives
    4.
    发明授权
    Imidazole, triazole and tetrazole derivatives 失效
    咪唑,三唑和四唑衍生物

    公开(公告)号:US5510362A

    公开(公告)日:1996-04-23

    申请号:US295884

    申请日:1994-09-08

    摘要: A class of substituted imidazole, triazole and tetrazole derivatives of formula (I), wherein the broken circle represents two non-adjacent double bonds in any position in the five-membered ring; two, three or four of V,W,X,Y and Z represent nitrogen and the remainder represent carbon provided that, when two of V,W,X,Y and Z represent nitrogen and the remainder represent carbon, then the said nitrogen atoms are in non-adjacent positions within the five-membered ring; E represents a bond or a straight or branched alkylene chain containing from 1 to 4 carbon atoms; F represents a group of formula (lI); U represents nitrogen or C--R.sup.2 ; B represents oxygen, sulphur or N--R.sup.3 ; are selective agonists of 5--HT.sub.1 -like receptors and are therefore useful in the treatment of clinical conditions, in particular migraine and associated disorders, for which a selective agonist of these receptors is indicated.

    摘要翻译: PCT No.PCT / GB93 / 00474 Sec。 371日期1994年9月8日 102(e)1994年9月8日PCT 1993年3月5日PCT公布。 公开号WO93 / 18029 (I)一类式(I)的取代的咪唑,三唑和四唑衍生物,其中,所述断圆代表在任何位置上的两个不相邻的双键 五元环; V,W,X,Y和Z中的两个,三个或四个表示氮,余数表示碳,条件是当V,W,X,Y和Z中的两个表示氮并且其余表示碳时,则所述氮原子 在五元环内的非相邻位置; E表示含有1至4个碳原子的键或直链或支链亚烷基链; F表示式(I)的基团; U表示氮或C-R2; B代表氧,硫或N-R3; 是5-HT1样受体的选择性激动剂,因此可用于治疗临床状况,特别是偏头痛和相关疾病,其中指出了这些受体的选择性激动剂。

    Benzodiazepine derivatives
    10.
    发明授权
    Benzodiazepine derivatives 失效
    苯并二氮杂衍生物

    公开(公告)号:US5521175A

    公开(公告)日:1996-05-28

    申请号:US374749

    申请日:1995-01-26

    摘要: Compounds of Formula (I), and salts and prodrugs thereof, wherein R.sup.1 represents C.sub.1-6 alkyl or C.sub.3-7 cycloalkyl; R.sup.2 optionally substituted phenyl or R.sup.2 represents a group (A) where W is CH.sub.2 or NR.sup.10, and W.sup.1 is CH.sub.2, or W and W.sup.1 each represent 0; R.sup.3 is C.sub.1-6 alkyl, halo or NR.sup.13 R.sup.14 ; R.sup.4 is H, C.sub.1-4 alkyl, optionally substituted phenyl or optionally substituted benzyl; R.sup.5, R.sup.6, R.sup.7 and R.sup.8 are H or C.sub.1-4 alkyl; or any two of R.sup.4, R.sup.5, R.sup.6, R.sup.7 and R.sup.8 together form a chain (CH.sub.2).sub.t, and any other two of R.sup.4, R.sup.5, R.sup.6, R.sup.7 and R.sup.8 optionally form a chain (CH.sub.2).sub.s where s and t are independently 1, 2 or 3; m is 2, 3, 4, 5, 6, 7, 8 or 9; n is 0, 1, 2, 3 or 4; and x is 0, 1, 2 or 3; are CCK and/or gastrin antagonists useful in therapy. ##STR1##

    摘要翻译: PCT No.PCT / GB93 / 01600 Sec。 371日期1995年1月26日 102(e)日期1995年1月26日PCT提交1993年7月28日PCT公布。 第WO94 / 03447号公报 日期:1994年2月17日。式(I)化合物及其盐和前药,其中R 1表示C 1-6烷基或C 3-7环烷基; R2任选取代的苯基或R 2表示其中W是CH 2或NR 10,且W 1是CH 2的基团(A),或者W和W 1各自表示0; R3是C1-6烷基,卤素或NR13R14; R 4是H,C 1-4烷基,任选取代的苯基或任选取代的苄基; R5,R6,R7和R8是H或C1-4烷基; 或R 4,R 5,R 6,R 7和R 8中的任何一个一起形成链(CH 2)t,并且R 4,R 5,R 6,R 7和R 8中的任何其它两个可任选地形成链(CH 2)s,其中s和t独立地 1,2或3; m为2,3,4,5,6,7,8或9; n为0,1,2,3或4; x为0,1,2或3; 是用于治疗的CCK和/或胃泌素拮抗剂。 (图)(一)